Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 55

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 55
---
624,000 |     |         $642,720 |     | 3.0%                  |
| Blaine Davis                   |     |         $440,000 |     |         $462,000 |     | 5.0%                  |
| Metin Kurtoglu, M.D., Ph.D.(1) |     |         $402,500 |     |         $440,000 |     | 9.3%                  |
| Christopher Jewell, Ph.D.(2)   |     |         $300,000 |     |         $420,000 |     | 40.0%                 |

(1) Dr. Kurtoglu was appointed to serve as the Company’s Chief Operating Officer on November 13, 2023. On March 28, 2024, Dr. Kurtoglu’s title was changed to Chief Technology Officer. Dr. Kurtoglu’s 2024 base salary went into effect on March 28, 2024.

(2) Dr. Jewell was appointed to serve as the Company’s Chief Scientific Officer on November 13, 2023. Dr. Jewell’s 2024 base salary went into effect on March 26, 2024. In 2024 Dr. Jewell’s salary was increased by 40% to bring his total compensation in line with market benchmarking.

#### Annual Cash Bonuses
We use annual bonuses paid to motivate our executive officers, including our Named Executive Officers, to achieve our short-term financial and operational objectives while making progress towards our longer-term growth and other goals. Consistent with our executive compensation philosophy, these annual bonuses are intended to help us to deliver a competitive total direct compensation opportunity to our executive officers. Annual cash bonuses are entirely performance-based, are not guaranteed, and may vary materially from year-to-year.

Typically, the Compensation Committee establishes cash bonus opportunities pursuant to a set of board-approved corporate goals that measures and rewards our executive officers for our actual corporate and their individual performance over our fiscal year. The cash bonus plan is designed to pay above-target bonuses when we exceed our annual corporate objectives and below-target bonuses when we do not achieve these objectives.

In December 2024, the Compensation Committee determined to award cash bonus opportunities to our executive officers, including our Named Executive Officers, pursuant to the 2024 Bonus Plan. Under the 2024 Bonus Plan, the Compensation Committee had the authority to select the performance measures and related target levels applicable to the annual cash bonus opportunities for our executive